Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedJul 07, 2026
DataAggregated Company Financials
Companies319
  • 7D-1.3%
  • 3M13.7%
  • 1Y47.9%
  • YTD13.3%

Over the last 7 days, the Pharma industry has dropped 1.3%, driven by Eli Lilly declining 2.4%. Meanwhile, Teva Pharmaceutical Industries actually outperformed within the industry, gaining 5.9% in the last week. This takes the industry's 12 month performance to a gain of 48%. As for the next few years, earnings are expected to grow by 14% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 08 Jul 2026US$2.6tUS$425.2bUS$65.8b15.3x39.6x6.1x
Fri, 05 Jun 2026US$2.3tUS$424.1bUS$66.3b15.3x35x5.5x
Sun, 03 May 2026US$2.3tUS$416.3bUS$62.4b17x36.1x5.4x
Tue, 31 Mar 2026US$2.2tUS$405.9bUS$71.8b16.7x30.7x5.4x
Thu, 26 Feb 2026US$2.4tUS$405.7bUS$73.4b19.9x32.8x5.9x
Sat, 24 Jan 2026US$2.3tUS$404.7bUS$73.2b19.8x31.7x5.7x
Mon, 22 Dec 2025US$2.2tUS$402.8bUS$71.4b19.8x31.3x5.5x
Wed, 19 Nov 2025US$2.1tUS$402.7bUS$71.5b19.4x29.6x5.2x
Fri, 17 Oct 2025US$1.9tUS$389.2bUS$63.5b18x29.6x4.8x
Sun, 14 Sep 2025US$1.8tUS$387.9bUS$60.9b18.9x29.3x4.6x
Tue, 12 Aug 2025US$1.6tUS$387.9bUS$60.7b18.5x27x4.2x
Thu, 10 Jul 2025US$1.7tUS$382.7bUS$61.3b18.1x28.4x4.6x
Sat, 07 Jun 2025US$1.7tUS$382.7bUS$61.2b17.1x27.9x4.5x
Mon, 05 May 2025US$1.8tUS$382.7bUS$63.7b17.2x27.8x4.6x
Wed, 02 Apr 2025US$1.9tUS$380.6bUS$41.2b16.2x45.2x4.9x
Fri, 28 Feb 2025US$1.9tUS$381.0bUS$39.4b16.4x49.1x5.1x
Sun, 26 Jan 2025US$1.8tUS$370.4bUS$30.5b18.4x59.1x4.9x
Tue, 24 Dec 2024US$1.8tUS$369.4bUS$31.1b16.7x57.2x4.8x
Thu, 21 Nov 2024US$1.8tUS$373.8bUS$30.6b20.1x58.1x4.7x
Sat, 19 Oct 2024US$2.0tUS$365.3bUS$23.7b18.6x85.8x5.6x
Mon, 16 Sep 2024US$2.0tUS$364.3bUS$25.4b18.8x80.2x5.6x
Wed, 14 Aug 2024US$2.0tUS$362.1bUS$22.0b17.4x89x5.4x
Fri, 12 Jul 2024US$2.0tUS$357.6bUS$13.8b15.9x144.8x5.6x
Sun, 09 Jun 2024US$1.9tUS$358.3bUS$14.1b15.6x136.8x5.4x
Tue, 07 May 2024US$1.8tUS$358.0bUS$13.8b21.1x133.7x5.1x
Thu, 04 Apr 2024US$1.9tUS$355.2bUS$22.7b24.6x82.9x5.3x
Sat, 02 Mar 2024US$1.9tUS$355.3bUS$22.5b24.1x83.8x5.3x
Mon, 29 Jan 2024US$1.8tUS$375.2bUS$33.9b24.6x52.1x4.7x
Wed, 27 Dec 2023US$1.7tUS$375.2bUS$33.9b31.8x49.3x4.4x
Fri, 24 Nov 2023US$1.6tUS$375.1bUS$33.9b25.9x48.2x4.4x
Sun, 22 Oct 2023US$1.7tUS$382.7bUS$44.7b17.6x37x4.3x
Tue, 19 Sep 2023US$1.7tUS$381.8bUS$43.9b18.5x39.1x4.5x
Thu, 17 Aug 2023US$1.8tUS$381.7bUS$44.0b19.1x40.2x4.6x
Sat, 15 Jul 2023US$1.7tUS$392.8bUS$60.2b18.3x27.7x4.2x
Price to Earnings Ratio

27.7x


Total Market Cap: US$1.7tTotal Earnings: US$60.2bTotal Revenue: US$392.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 54.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 39.6x which is lower than its 3-year average PE of 54.3x.
  • The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 6.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 3.0% per year over the last three years.
  • Revenues for these companies have grown 2.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.79%
Healthcare0.97%
Pharma-1.31%
Pharma-1.31%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.24k3.0%
+US$32.2b		58.9%PE43.6x
JNJ Johnson & JohnsonUS$267.245.2%
+US$31.9b		71.5%PE30.6x
CRNX Crinetics PharmaceuticalsUS$83.53123.2%
+US$4.9b		184.4%PS487.4x
ZTS ZoetisUS$76.296.2%
+US$1.9b		-51.7%PE12x
VTRS ViatrisUS$16.966.8%
+US$1.3b		83.2%PS1.4x

Latest News

CRNX
US$83.53
Crinetics Pharmaceuticals
7D
123.2%
1Y
184.4%
TEVA
US$34.65
Teva Pharmaceutical Industries
7D
2.3%
1Y
108.4%
ZTS
US$76.29
Zoetis
7D
6.2%
1Y
-51.7%
MRK
US$128.86
Merck
7D
0.3%
1Y
58.4%
TRLV
US$8.93
Trulieve Cannabis
7D
-9.2%
1Y
111.9%
JNJ
US$267.24
Johnson & Johnson
7D
5.2%
1Y
71.5%
Narrative Update • Jul 03

JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules

For Johnson & Johnson, the analyst price target has been revised higher. The updated fair value estimate has moved from about $181.77 to $212.24 as analysts factor in refreshed revenue growth assumptions, slightly adjusted discount and margin inputs, and a higher future P/E in light of recent research pointing to ongoing new drug momentum and broadly supportive earnings expectations.
RPRX
US$57.80
Royalty Pharma
7D
3.1%
1Y
62.8%
Narrative Update • Jul 03

RPRX: Royalty Deals And Buybacks Will Test Rich Earnings Assumptions

Royalty Pharma's analyst price target has shifted modestly higher, with updated fair value estimates moving from $46.00 to about $47.90 as analysts factor in revised assumptions around revenue growth, profit margins, and future P/E expectations. Analyst Commentary on Royalty Pharma Recent Street research on Royalty Pharma points to a more cautious tone beneath the modestly higher fair value estimates.
DFTX
US$44.48
Definium Therapeutics
7D
-5.4%
1Y
495.4%
RAPP
US$39.73
Rapport Therapeutics
7D
-4.7%
1Y
214.8%
VTRS
US$16.96
Viatris
7D
6.8%
1Y
83.2%
LLY
US$1,235.56
Eli Lilly
7D
3.0%
1Y
58.9%
AMRX
US$17.05
Amneal Pharmaceuticals
7D
-1.5%
1Y
106.7%
SPTX
US$18.23
Seaport Therapeutics
7D
-16.1%
1Y
n/a
AVLN
US$28.42
Avalyn Pharma
7D
-13.7%
1Y
n/a
SGP
US$19.52
SpyGlass Pharma
7D
-12.3%
1Y
n/a
MANE
US$116.80
Veradermics
7D
-5.0%
1Y
n/a